Peptides developed by Michigan researchers could lead to a targeted therapy for half of all prostate cancer patients.
Neurovascular bundles are spared if intraoperative pathologic examination of tissue adjacent to the bundles following removal of the prostate shows negative surgical margins.
A urologist explains the benefits of a relatively new robotic procedure for men with prostate cancer.
Targeting CYP11A1 provides a compelling approach to suppressing the production of steroid hormones, a key driver of prostate cancer.
AstraZeneca and Merck’s Lynparza won an FDA go-ahead in prostate cancer this past May.